Homestead Advisers Corp Buys 90,100 Shares of ADMA Biologics Inc $ADMA

Homestead Advisers Corp boosted its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 83.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 198,500 shares of the biotechnology company’s stock after buying an additional 90,100 shares during the quarter. Homestead Advisers Corp’s holdings in ADMA Biologics were worth $2,910,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in ADMA. Thrivent Financial for Lutherans lifted its stake in shares of ADMA Biologics by 78.1% during the second quarter. Thrivent Financial for Lutherans now owns 3,315,425 shares of the biotechnology company’s stock valued at $60,373,000 after acquiring an additional 1,453,924 shares during the period. Franklin Resources Inc. raised its holdings in ADMA Biologics by 66.4% during the 2nd quarter. Franklin Resources Inc. now owns 2,719,016 shares of the biotechnology company’s stock worth $49,513,000 after purchasing an additional 1,085,286 shares during the last quarter. First Light Asset Management LLC bought a new stake in ADMA Biologics during the 2nd quarter worth about $17,338,000. Ranger Investment Management L.P. lifted its position in ADMA Biologics by 49.1% during the 2nd quarter. Ranger Investment Management L.P. now owns 2,390,375 shares of the biotechnology company’s stock valued at $43,529,000 after purchasing an additional 786,865 shares during the period. Finally, State Street Corp boosted its stake in shares of ADMA Biologics by 5.6% in the 2nd quarter. State Street Corp now owns 12,078,505 shares of the biotechnology company’s stock valued at $219,950,000 after purchasing an additional 637,727 shares during the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, ADMA Biologics presently has a consensus rating of “Buy” and a consensus target price of $28.50.

ADMA Biologics Price Performance

Shares of ADMA opened at $16.49 on Thursday. The company has a current ratio of 7.13, a quick ratio of 3.65 and a debt-to-equity ratio of 0.18. ADMA Biologics Inc has a 1 year low of $13.50 and a 1 year high of $25.67. The stock has a market cap of $3.92 billion, a P/E ratio of 19.17 and a beta of 0.49. The stock’s 50-day moving average price is $18.47 and its two-hundred day moving average price is $17.03.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting analysts’ consensus estimates of $0.16. ADMA Biologics had a return on equity of 36.52% and a net margin of 42.87%.The company had revenue of $134.22 million during the quarter, compared to analysts’ expectations of $131.20 million. During the same period in the prior year, the business posted $0.15 EPS. ADMA Biologics’s revenue was up 12.0% on a year-over-year basis. On average, equities analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.